Cargando…

PPIs therapy has a negative impact on the clinical outcomes of advanced SCLC patients treated with PD-L1 inhibitors

BACKGROUND: Programmed death-ligand 1 (PD-L1) inhibitors has emerged as a first-line therapeutic strategy for advanced small cell lung cancer (SCLC), which can stimulate T-cell activation, thereby preventing tumor avoidance of immunologic surveillance, whereas, proton pump inhibitors (PPIs) can play...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Sisi, Tian, Jing, Wang, Xinwei, Liu, Chengxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638834/ https://www.ncbi.nlm.nih.gov/pubmed/37951887 http://dx.doi.org/10.1186/s12890-023-02754-4

Ejemplares similares

Rebamipide with Proton Pump Inhibitors (PPIs) versus PPIs Alone for the Treatment of Endoscopic Submucosal Dissection-Induced Ulcers: A Meta-analysis
por: Liu, Junyuan, et al.
Publicado: (2020)

Prognostic Nutritional Index Predicts Outcome of PD-L1 Negative and MSS Advanced Cancer Treated with PD-1 Inhibitors
por: Zhang, Yan, et al.
Publicado: (2022)

Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy
por: Zhang, Lilong, et al.
Publicado: (2022)

Impact of PPIs on patient focused symptomatology in GERD
por: Thomson, ABR
Publicado: (2008)

Prevalence and Safety of Prescribing PPIs with Clopidogrel in Palestine
por: Abukhalil, Abdallah Damin, et al.
Publicado: (2023)

PPIs and gastric cancer: any causal relationship?
por: Crafa, Pellegrino, et al.
Publicado: (2023)

Editorial: Influence of Protein-Protein Interactions (PPIs) on the Outcome of Viral Infections
por: Jangra, Rohit K., et al.
Publicado: (2022)

Therapeutic Efficacy of Kangfuxin Liquid Combined with PPIs in Gastric Ulcer
por: Zou, Jun-Bo, et al.
Publicado: (2019)

Current status of acid pump antagonists (reversible PPIs).
por: Wurst, W., et al.
Publicado: (1996)

Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study
por: Wang, Lihua, et al.
Publicado: (2022)

Exploratory Study of Tegaserod for Dyspepsia in Women Receiving PPIs for Heartburn
por: Vakil, Nimish, et al.
Publicado: (2008)

Synthesis and Activity of Ionic Antioxidant-Functionalized PAMAMs and PPIs Dendrimers
por: Bacha, Katia, et al.
Publicado: (2022)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
por: Zhang, Chenyue, et al.
Publicado: (2021)

Retracted: Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Unintended effects of proton pump inhibitors (PPIs) in patients with glioblastoma (GBM): A double-edged sword
por: Castro, Michael P
Publicado: (2022)

Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials
por: Facchinetti, Francesco, et al.
Publicado: (2020)

Laparoscopic antireflux surgery or PPIs in the management of reflux-related esophageal stricture
por: Li, Zhi-tong, et al.
Publicado: (2022)

The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
por: Kanemura, Hiroaki, et al.
Publicado: (2022)

Sonic Hedgehog in SCLC
por: Laukkanen, Mikko O., et al.
Publicado: (2015)

Pathology and Classification of SCLC
por: Raso, Maria Gabriela, et al.
Publicado: (2021)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Effect of PPIs on symptomatic hypocalcemia after thyroidectomy: A retrospective cohort study
por: Gerges, Daniel, et al.
Publicado: (2020)

PPIs Are Therapeutically Interchangeable and Ideal for a Managed Care Intervention Such as Therapeutic MAC
por: Crownover, Brian K.
Publicado: (2006)

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?
por: Domvri, Kalliopi, et al.
Publicado: (2015)

Strategies for discontinuation of proton pump inhibitors (PPIs) in patients with long-term PPI administration: a randomized controlled trial
por: Hojo, Mariko, et al.
Publicado: (2022)

Is transformed small cell lung cancer (SCLC) different from de novo SCLC?
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy
por: Bütof, Rebecca, et al.
Publicado: (2017)

What Are the Biomarkers for Immunotherapy in SCLC?
por: Longo, Vito, et al.
Publicado: (2021)

Prophylactic cranial irradiation in SCLC
por: Suwinski, Rafal
Publicado: (2021)

On the Acquisition of Polarity Items: 11- to 12-Year-Olds' Comprehension of German NPIs and PPIs
por: Schwab, Juliane, et al.
Publicado: (2021)

No evidence for the benefit of PPIs in the treatment of acute pancreatitis: a systematic review and meta-analysis
por: Horváth, István László, et al.
Publicado: (2023)

Analysis of Nonformulary Use of PPIs and Excess Drug Cost in a Veterans Affairs Population
por: Ajumobi, Adewale B., et al.
Publicado: (2012)

The effect of gender on the clinical outcome of PD-1/PD-L1 inhibitor in advanced lung cancer patients
por: Wu, Bing, et al.
Publicado: (2023)

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors
por: Peng, Lihong, et al.
Publicado: (2020)

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC
por: Taniguchi, Hirokazu, et al.
Publicado: (2022)

Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China
por: Zhou, Dongchu, et al.
Publicado: (2023)

Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1
por: Li, Yixiang, et al.
Publicado: (2023)

What's New in SCLC? A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel—A Systematic Review and Meta-Analysis
por: Demcsák, Alexandra, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5fpfvod01qnn09b49alljh56k6